Gilead Discontinues Study of Immunotherapy to Treat Blood Cancers

By Denny Jacob

Gilead Sciences has discontinued its Phase 3 study of magrolimab in higher-risk myelodysplastic syndromes.

The biopharmaceutical company said on Friday the study was discontinued due to futility based on a planned analysis. Gilead said it recommends discontinuing treatment with magrolimab in patients with myelodysplastic syndromes,…